Drugs / IVA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04353817 | Jun 2020 → May 2021 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04353817 ↗ |
| Route | Oral | “Tablet for oral administration qd in the evening.” NCT04353817 ↗ |